Innate Pharma reports €96.8M in cash, outlines key 2027 pipeline milestones (IPHA:NASDAQ)

Innate Pharma reported 9M revenue of €3.4M, up from €2.3M a year ago. The company had €96.8M in cash at September 30, 2026, including funds from a Sobi transaction and private placement. It outlined key 2027 pipeline milestones.

Original reporting
Published Nov 5, 2026, 10:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IPHA
Neutral
medium confidence
Mentioned
$IPHA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IPHANeutralLow
01

Why it matters

The cash update provides a baseline for liquidity assessment ahead of upcoming trial readouts.

02

Market read

A modest cash position update with limited immediate trading impact.

03

What to watch

Potential upcoming partnership or grant not disclosed could change the outlook.

Relevance 6/10Novelty 5/10Timing: same-day release

Background

Innate Pharma is a clinical‑stage immuno‑oncology company listed on NASDAQ under IPHA.

Company-level read

Ticker impact

$IPHANeutralMedium confidence
Context

Press release discloses €96.8M cash and €3.4M revenue for Q3 2026, new financial figures for the company.

Expected impact

potential modest pressure as market prices in limited cash position

Evidence & confidence

The disclosed cash amount is modest for a biotech; no major catalyst beyond the update, so price move likely limited.

Market effects

Minor signal for European biotech cash‑burn trends.

Limited impact on broader European markets.

Low relevance globally.

Counterpoint

Investors could see the cash balance as a floor supporting future R&D spend.

Key entities

  • Innate Pharma

    Biotech firm reporting cash and revenue figures.

Related articles

$IPHAHighAI 8/10

Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

$IPHAMed

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.